Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators.

Lancet. 2009 Feb 28;373(9665):723-31. doi: 10.1016/S0140-6736(09)60441-4.

PMID:
19249633
2.

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM; TRITON-TIMI 38 Investigators.

Lancet. 2008 Apr 19;371(9621):1353-63. doi: 10.1016/S0140-6736(08)60422-5. Epub 2008 Apr 2.

PMID:
18377975
3.

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators.

N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.

4.

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.

Wilcox R, Iqbal K, Costigan T, Lopez-Sendon J, Ramos Y, Widimsky P.

Curr Med Res Opin. 2014 Nov;30(11):2193-205. doi: 10.1185/03007995.2014.944638. Epub 2014 Aug 6.

PMID:
25025610
5.
6.

Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).

Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Am Heart J. 2006 Oct;152(4):627-35.

PMID:
16996826
8.

Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.

De Servi S, Goedicke J, Schirmer A, Widimsky P.

Eur Heart J Acute Cardiovasc Care. 2014 Dec;3(4):363-72. doi: 10.1177/2048872614534078. Epub 2014 May 12.

PMID:
24818952
9.

Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).

Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD.

JACC Cardiovasc Interv. 2014 Jun;7(6):604-12. doi: 10.1016/j.jcin.2014.01.160. Erratum in: JACC Cardiovasc Interv. 2014 Aug;7(8):946. Antman, Elliot M [Corrected to Antman, Elliott M].

10.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

12.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

14.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

15.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.

Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.

16.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

17.

Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.

Montalescot G, Collet JP, Ecollan P, Bolognese L, Ten Berg J, Dudek D, Hamm C, Widimsky P, Tanguay JF, Goldstein P, Brown E, Miller DL, LeNarz L, Vicaut E; ACCOAST Investigators.

J Am Coll Cardiol. 2014 Dec 23;64(24):2563-71. doi: 10.1016/j.jacc.2014.08.053.

18.

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.

Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D, Hafley G, Lokhnygina Y, Boden WE, Hamm C, Clemmensen P, Nicolau JC, Menozzi A, Ruzyllo W, Widimsky P, Oto A, Leiva-Pons J, Pavlides G, Winters KJ, Roe MT, Bhatt DL.

Lancet. 2013 Aug 17;382(9892):605-13. doi: 10.1016/S0140-6736(13)61451-8. Erratum in: Lancet. 2013 Aug 31;382(9894):768.

PMID:
23953385
19.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
20.

Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):193-5.

PMID:
19877380
Items per page

Supplemental Content

Write to the Help Desk